FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Molecular Diagnostics Market Overview:

According to FutureWise analysis the market for Molecular Diagnostics in 2023 is US$ 15.6 billion, and is expected to reach US$ 37.59 billion by 2031 at a CAGR of 11.62%.

Molecular diagnostics is a field of medical testing that focuses on the identification and analysis of molecules at the molecular level, including nucleic acids and proteins. It involves using advanced laboratory techniques to identify and measure specific biomarkers that are indicative of disease or other health conditions. Molecular diagnostics can be used for a variety of purposes, including the detection of infectious diseases, genetic disorders, and cancers. By analyzing the specific molecular characteristics of a patient's sample, molecular diagnostics can provide a more accurate and precise diagnosis compared to traditional methods.

There are several different types of molecular diagnostic tests available, including next-generation sequencing (NGS), PCR, and fluorescent in situ hybridization (FISH). Each of these techniques uses different methods to identify and measure specific molecules, depending on the type of analysis required. Molecular diagnostics is becoming increasingly important in the field of individualized medicine, which aims to tailor medical treatment to an individual's specific genetic makeup and other molecular characteristics. By analyzing a patient's molecular profile, doctors can identify the most effective treatment options and avoid treatments that may not be effective or may cause harmful side effects.

FutureWise Market Research has published a report that provides an insightful analysis of Molecular Diagnostics Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Molecular Diagnostics Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

Major players included in the Molecular Diagnostics Market:

F. Hoffmann-La Roche Ltd.
Hologic, Inc.
BioMérieux SA
Abbott Laboratories
Qiagen
Thermo Fisher Scientific Inc.
Siemens Healthineers AG
Danaher Corporation
Myriad Genetics Inc.
Illumina Inc.
Agilent Technologies Inc.
Becton, Dickinson and Company
DiaSorin S.p.A
Grifols S.A.
Quidel Corporation
Genetic Signatures
MDxHealth, Inc.
Exact Sciences Corporation
Biocartis NV
TBG Diagnostics Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Molecular Diagnostics Market:

In October 2022, a CE-IVD marked panel called the TaqPath Enteric Bacterial Select Panel was introduced by Thermo Fisher Scientific to quickly identify common gastrointestinal bacteria.

The molecular diagnostics industry is expanding at a fast pace, driven by advancements in genomics and proteomics, as well as increasing demand for personalized medicine. One of the major driving forces of the molecular diagnostics market is the increasing prevalence of infectious diseases and genetic disorders. With the rise of global travel and urbanization, the spread of infectious diseases has become more common, making accurate and timely diagnosis critical for effective treatment. In addition, advances in genetic testing have made it possible to detect genetic mutations associated with inherited disorders, allowing for early intervention and personalized treatment. Another factor propelling the growth of the molecular diagnostics market is the increasing availability of affordable and portable testing devices. These tools are designed to offer accurate and rapid diagnosis in a variety of settings, including hospitals, clinics, and even at home. This has increased the demand for point-of-care testing, which allows for faster and more efficient diagnosis and can reduce healthcare costs.

However, there are also some challenges facing the molecular diagnostics market. One major challenge is the lack of reimbursement for molecular diagnostic tests in many countries. This can limit the adoption of molecular diagnostics, especially in low- and middle-income countries. Another challenge is the high cost of molecular diagnostic tests, which can make them inaccessible to many patients. This is particularly true for NGS tests, which can be very expensive.

Molecular Diagnostics Market Segmentation:

By Product

Reagents & kits
Instruments
- Tabletop Instruments
- Portable & PoC Instruments
Services & Software

By Technology

Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
DNA Sequencing & Next-Generation Sequencing (NGS)
In Situ Hybridization (ISH)
DNA Microarrays
Other technologies

By Application

Infectious Disease Diagnostics
- COVID-19
- Hepatitis
- HIV
- CT/NG
- HAI
- HPV
- Tuberculosis
- Influenza
- Other Infectious Diseases
Oncology Testing
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Other Cancers
Genetic Tests
Other Applications

By End User

Diagnostic Laboratories
Hospitals and Clinics
Other End Users

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. Large bacterial and viral epidemic outbreaks, the rising need for point-of-care diagnostics, quickly advancing technology, and the consistent presence of leading market players in the region are some of the factors boosting the market growth in this region. The field of molecular diagnostics has significantly changed how diseases are diagnosed, allowing for quick identification and precise treatment of individuals who are severely ill. Traditional diagnostic techniques are being replaced by molecular diagnostics as a result of rising per capita health expenditures, improvements in the healthcare system, and an increase in the incidence of infectious illnesses and cancer in the United States. For instance, the ACS "Cancer Facts & Figures 2022" estimates that there were around 1,918,030 new cancer cases in the United States in 2022. Because of the high prevalence of cancer in this region, molecular diagnostics are expected to become more widely used to diagnose cancer, leading to market growth

Molecular Diagnostics Market Sample Video:

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Molecular Diagnostics Market By Product, By Technology, By Application, By End User and By Region.
[To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To record and evaluate competitive landscape mapping- Product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1 . Years Considered for the Study
  3.2 . Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1 . Secondary Data
  1.1.1 . Key Data from Secondary Sources
  1.2 . Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Molecular Diagnostics Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Molecular Diagnostics Market Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Molecular Diagnostics Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Molecular Diagnostics Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Reagents and kits
  2. Instruments
  2.1. Tabletop Instruments
  2.2. Portable nand PoC Instruments
  3. Services and Software
8. Molecular Diagnostics Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Polymerase Chain Reaction (PCR)
  2. Isothermal Nucleic Acid Amplification Technology (INAAT)
  3. DNA Sequencing and Next-Generation Sequencing (NGS)
  4. In Situ Hybridization (ISH)
  5. DNA Microarrays
  6. Other technologies
9. Molecular Diagnostics Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Infectious Disease Diagnostics
  1.1. COVID-19
  1.2. Hepatitis
  1.3. HIV
  1.4. CT/NG
  1.5. HAI
  1.6. HPV
  1.7. Tuberculosis
  1.8. Influenza
  1.9. Other Infectious Diseases
  2. Oncology Testing
  2.1. Breast Cancer
  2.2. Colorectal Cancer
  2.3. Lung Cancer
  2.4. Prostate Cancer
  2.5. Other Cancers
  3. Genetic Tests
  4. Other Applications
10. Molecular Diagnostics Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Diagnostic Laboratories
  2. Hospitals and Clinics
  3. Other End Users
11. North America Molecular Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
12. Latin America Molecular Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
13. Europe Molecular Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
14. Asia Pacific Molecular Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
15. Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
16. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. F. Hoffmann-La Roche Ltd.
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Hologic, Inc.
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. BioMérieux SA
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Abbott Laboratories
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. Qiagen
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Thermo Fisher Scientific Inc.
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. Siemens Healthineers AG
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Danaher Corporation
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Myriad Genetics Inc.
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
  10. Illumina Inc.
  10.1.Company Overview
  10.2.Product Portfolio
  10.3.SWOT Analysis
  10.4.Financial Overview
  10.5.Strategic Overview
  11. Agilent Technologies Inc.
  11.1.Company Overview
  11.2.Product Portfolio
  11.3.SWOT Analysis
  11.4.Financial Overview
  11.5.Strategic Overview
  12. Becton, Dickinson and Company
  12.1.Company Overview
  12.2.Product Portfolio
  12.3.SWOT Analysis
  12.4.Financial Overview
  12.5.Strategic Overview
  13. DiaSorin S.p.A
  13.1.Company Overview
  13.2.Product Portfolio
  13.3.SWOT Analysis
  13.4.Financial Overview
  13.5.Strategic Overview
  14. Grifols S.A.
  14.1.Company Overview
  14.2.Product Portfolio
  14.3.SWOT Analysis
  14.4.Financial Overview
  14.5.Strategic Overview
  15. Quidel Corporation
  15.1.Company Overview
  15.2.Product Portfolio
  15.3.SWOT Analysis
  15.4.Financial Overview
  15.5.Strategic Overview
  16. Genetic Signatures
  16.1.Company Overview
  16.2.Product Portfolio
  16.3.SWOT Analysis
  16.4.Financial Overview
  16.5.Strategic Overview
  17. MDxHealth, Inc.
  1.Company Overview
  2.Product Portfolio
  3.SWOT Analysis
  4.Financial Overview
  5.Strategic Overview
  18. Exact Sciences Corporation
  18.1.Company Overview
  18.2.Product Portfolio
  18.3.SWOT Analysis
  18.4.Financial Overview
  18.5.Strategic Overview
  19.Biocartis NV
  19.1.Company Overview
  19.2.Product Portfolio
  19.3.SWOT Analysis
  19.4.Financial Overview
  19.5.Strategic Overview
  20. TBG Diagnostics Ltd.
  20.1.Company Overview
  20.2.Product Portfolio
  20.3.SWOT Analysis
  20.4.Financial Overview
  20.5.Strategic Overview
18. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the healthcare regulations initiated by administrations
  5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients